Annual Book Value
$63.42 M
$61.03 M-13.53%
31 December 2023
Summary:
Lineage Cell Therapeutics annual book value is currently $63.42 million, with the most recent change of +$61.03 million (-13.53%) on 31 December 2023. During the last 3 years, it has fallen by -$32.78 million (-34.08%). LCTX annual book value is now -61.01% below its all-time high of $162.64 million, reached on 31 December 2017.LCTX Book Value Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Book Value
$66.19 M
-$2.11 M-3.10%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly book value is currently $66.19 million, with the most recent change of -$2.11 million (-3.10%) on 30 September 2024. Over the past year, it has dropped by -$1.93 million (-2.83%). LCTX quarterly book value is now -66.62% below its all-time high of $198.29 million, reached on 30 September 2017.LCTX Quarterly Book Value Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Book Value Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -13.5% | -2.8% |
| 3 y3 years | -34.1% | -45.2% |
| 5 y5 years | -32.4% | -43.5% |
LCTX Book Value High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -34.1% | at low | -45.2% | +4.4% |
| 5 y | 5 years | -43.9% | at low | -46.9% | +4.4% |
| alltime | all time | -61.0% | +1559.0% | -66.6% | +1439.9% |
Lineage Cell Therapeutics Book Value History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $66.19 M(-3.1%) |
| June 2024 | - | $68.30 M(-5.7%) |
| Mar 2024 | - | $72.40 M(+14.2%) |
| Dec 2023 | $63.42 M(-13.5%) | $63.42 M(-6.9%) |
| Sept 2023 | - | $68.12 M(-6.3%) |
| June 2023 | - | $72.67 M(+3.1%) |
| Mar 2023 | - | $70.45 M(-3.9%) |
| Dec 2022 | $73.34 M(-20.5%) | $73.34 M(-7.1%) |
| Sept 2022 | - | $78.95 M(-4.7%) |
| June 2022 | - | $82.85 M(-4.3%) |
| Mar 2022 | - | $86.55 M(-6.2%) |
| Dec 2021 | $92.22 M(-4.1%) | $92.22 M(-23.6%) |
| Sept 2021 | - | $120.71 M(-3.2%) |
| June 2021 | - | $124.71 M(+6.0%) |
| Mar 2021 | - | $117.67 M(+22.3%) |
| Dec 2020 | $96.20 M(-14.8%) | $96.20 M(+5.4%) |
| Sept 2020 | - | $91.27 M(-8.2%) |
| June 2020 | - | $99.44 M(-6.6%) |
| Mar 2020 | - | $106.50 M(-5.7%) |
| Dec 2019 | $112.96 M(+20.4%) | $112.96 M(-3.6%) |
| Sept 2019 | - | $117.16 M(-12.2%) |
| June 2019 | - | $133.39 M(-18.1%) |
| Mar 2019 | - | $162.84 M(+73.5%) |
| Dec 2018 | $93.84 M(-42.3%) | $93.84 M(-45.2%) |
| Sept 2018 | - | $171.13 M(+69.5%) |
| June 2018 | - | $100.98 M(+1.0%) |
| Mar 2018 | - | $99.97 M(-38.5%) |
| Dec 2017 | $162.64 M(+37.9%) | $162.64 M(-18.0%) |
| Sept 2017 | - | $198.29 M(+12.6%) |
| June 2017 | - | $176.13 M(-6.0%) |
| Mar 2017 | - | $187.37 M(+58.9%) |
| Dec 2016 | $117.93 M(+356.8%) | $117.93 M(-1.2%) |
| Sept 2016 | - | $119.39 M(+39.2%) |
| June 2016 | - | $85.74 M(+690.1%) |
| Mar 2016 | - | $10.85 M(-58.0%) |
| Dec 2015 | $25.82 M(-21.7%) | $25.82 M(+97.9%) |
| Sept 2015 | - | $13.04 M(-3.2%) |
| June 2015 | - | $13.48 M(-40.8%) |
| Mar 2015 | - | $22.75 M(-31.0%) |
| Dec 2014 | $32.96 M(+122.7%) | $32.96 M(+340.5%) |
| Sept 2014 | - | $7.48 M(-48.1%) |
| June 2014 | - | $14.41 M(-8.5%) |
| Mar 2014 | - | $15.74 M(+6.4%) |
| Dec 2013 | $14.80 M(+54.4%) | $14.80 M(+14.4%) |
| Sept 2013 | - | $12.94 M(-38.1%) |
| June 2013 | - | $20.92 M(+32.0%) |
| Mar 2013 | - | $15.84 M(+65.3%) |
| Dec 2012 | $9.58 M(-66.5%) | $9.58 M(-43.4%) |
| Sept 2012 | - | $16.94 M(-26.9%) |
| June 2012 | - | $23.18 M(-4.2%) |
| Mar 2012 | - | $24.20 M(-15.5%) |
| Dec 2011 | $28.65 M(-25.0%) | $28.65 M(-14.8%) |
| Sept 2011 | - | $33.63 M(-7.0%) |
| June 2011 | - | $36.14 M(-11.5%) |
| Mar 2011 | - | $40.86 M(+7.0%) |
| Dec 2010 | $38.17 M(+441.7%) | $38.17 M(+8.6%) |
| Sept 2010 | - | $35.16 M(+26.6%) |
| June 2010 | - | $27.76 M(+331.0%) |
| Mar 2010 | - | $6.44 M(-8.6%) |
| Dec 2009 | $7.05 M(-262.1%) | $7.05 M(+69.9%) |
| Sept 2009 | - | $4.15 M(-600.9%) |
| June 2009 | - | -$827.80 K(-83.2%) |
| Mar 2009 | - | -$4.94 M(+13.6%) |
| Dec 2008 | -$4.35 M | -$4.35 M(-9.8%) |
| Sept 2008 | - | -$4.82 M(+22.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2008 | - | -$3.92 M(+17.1%) |
| Mar 2008 | - | -$3.35 M(+10.0%) |
| Dec 2007 | -$3.05 M(+63.3%) | -$3.05 M(+7.1%) |
| Sept 2007 | - | -$2.84 M(+7.9%) |
| June 2007 | - | -$2.64 M(+11.1%) |
| Mar 2007 | - | -$2.37 M(+27.2%) |
| Dec 2006 | -$1.87 M(+848.7%) | -$1.87 M(+19.8%) |
| Sept 2006 | - | -$1.56 M(+27.1%) |
| June 2006 | - | -$1.22 M(+96.2%) |
| Mar 2006 | - | -$624.40 K(+217.6%) |
| Dec 2005 | -$196.60 K(-157.0%) | -$196.60 K(-82.4%) |
| Sept 2005 | - | -$1.11 M(+50.4%) |
| June 2005 | - | -$740.40 K(+130.4%) |
| Mar 2005 | - | -$321.40 K(-193.2%) |
| Dec 2004 | $344.80 K(-114.2%) | $344.80 K(-60.8%) |
| Sept 2004 | - | $880.10 K(-34.0%) |
| June 2004 | - | $1.33 M(-21.7%) |
| Mar 2004 | - | $1.70 M(-170.0%) |
| Dec 2003 | -$2.43 M(+107.5%) | -$2.43 M(+33.1%) |
| Sept 2003 | - | -$1.83 M(-16.9%) |
| June 2003 | - | -$2.20 M(+24.3%) |
| Mar 2003 | - | -$1.77 M(+50.9%) |
| Dec 2002 | -$1.17 M(+1081.7%) | -$1.17 M(+227.8%) |
| Sept 2002 | - | -$357.30 K(-77.0%) |
| June 2002 | - | -$1.55 M(+108.0%) |
| Mar 2002 | - | -$746.80 K(+653.6%) |
| Dec 2001 | -$99.10 K(-107.5%) | -$99.10 K(-90.7%) |
| Sept 2001 | - | -$1.07 M(+528.2%) |
| June 2001 | - | -$170.10 K(-122.6%) |
| Mar 2001 | - | $754.00 K(-42.8%) |
| Dec 2000 | $1.32 M(-74.1%) | $1.32 M(-40.1%) |
| Sept 2000 | - | $2.20 M(-12.0%) |
| June 2000 | - | $2.50 M(-36.3%) |
| Mar 2000 | - | $3.92 M(-22.8%) |
| Dec 1999 | $5.08 M(+111.8%) | $5.08 M(-21.8%) |
| Sept 1999 | - | $6.50 M(-19.8%) |
| June 1999 | - | $8.10 M(-9.0%) |
| Mar 1999 | - | $8.90 M(+169.7%) |
| Dec 1998 | $2.40 M(-40.0%) | - |
| Sept 1998 | - | $3.30 M(-17.5%) |
| June 1998 | - | $4.00 M(-16.7%) |
| June 1998 | $4.00 M(-38.5%) | - |
| Mar 1998 | - | $4.80 M(-15.8%) |
| Dec 1997 | - | $5.70 M(-6.6%) |
| Sept 1997 | - | $6.10 M(-6.2%) |
| June 1997 | $6.50 M(+132.1%) | $6.50 M(-14.5%) |
| Mar 1997 | - | $7.60 M(+280.0%) |
| Dec 1996 | - | $2.00 M(-16.7%) |
| Sept 1996 | - | $2.40 M(-14.3%) |
| June 1996 | $2.80 M(-12.5%) | $2.80 M(-3.4%) |
| Sept 1995 | - | $2.90 M(-9.4%) |
| June 1995 | $3.20 M(-44.8%) | $3.20 M(-20.0%) |
| Mar 1995 | - | $4.00 M(-13.0%) |
| Dec 1994 | - | $4.60 M(-14.8%) |
| Sept 1994 | - | $5.40 M(-6.9%) |
| June 1994 | $5.80 M(+70.6%) | $5.80 M(-7.9%) |
| Mar 1994 | - | $6.30 M(+133.3%) |
| Dec 1993 | - | $2.70 M(-20.6%) |
| Sept 1993 | - | $3.40 M(0.0%) |
| June 1993 | $3.40 M(-26.1%) | $3.40 M(-10.5%) |
| Mar 1993 | - | $3.80 M(-5.0%) |
| Dec 1992 | - | $4.00 M(-9.1%) |
| Sept 1992 | - | $4.40 M(-4.3%) |
| June 1992 | $4.60 M | $4.60 M(-6.1%) |
| Mar 1992 | - | $4.90 M |
FAQ
- What is Lineage Cell Therapeutics annual book value?
- What is the all time high annual book value for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual book value year-on-year change?
- What is Lineage Cell Therapeutics quarterly book value?
- What is the all time high quarterly book value for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly book value year-on-year change?
What is Lineage Cell Therapeutics annual book value?
The current annual book value of LCTX is $63.42 M
What is the all time high annual book value for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual book value is $162.64 M
What is Lineage Cell Therapeutics annual book value year-on-year change?
Over the past year, LCTX annual book value has changed by -$9.92 M (-13.53%)
What is Lineage Cell Therapeutics quarterly book value?
The current quarterly book value of LCTX is $66.19 M
What is the all time high quarterly book value for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly book value is $198.29 M
What is Lineage Cell Therapeutics quarterly book value year-on-year change?
Over the past year, LCTX quarterly book value has changed by -$1.93 M (-2.83%)